Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

Raj Tummala,1 Gabriel Abreu,2 Lilia Pineda,1 M Alex Michaels,1 Rubana N Kalyani,1 Richard A Furie,3 Eric F Morand4

ABSTRACT

Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated the safety and tolerability of anifrolumab using data pooled from these trials to more precisely estimate the rate and severity of adverse events (AEs).

Methods Data were pooled from patients receiving monthly intravenous anifrolumab 300 mg or placebo in MUSE, TULIP-1 and TULIP-2. Key safety endpoints included percentages and exposure-adjusted incidence rates (EIRs) of patients who experienced AEs, serious AEs (SAEs), AEs leading to discontinuation and AEs of special interest.

Results During treatment, 86.9% of patients receiving anifrolumab 300 mg (n=459) experienced AEs (≥1) versus 79.4% receiving placebo (n=466), and 4.1% versus 5.2% experienced an AE leading to discontinuation of investigational product. SAEs (≥1) were experienced by 11.8% and 16.7% of patients receiving anifrolumab and placebo, respectively (EAIR risk difference (95% CI) −7.2 (−12.5 to −1.9)), including lupus exacerbations classified as SAEs (1.5% and 3%, respectively). Infections occurred in 69.7% and 55.4% of patients receiving anifrolumab and placebo, respectively; difference in reported rates was driven by herpes zoster (HZ) and mild and moderate respiratory (excluding pneumonia) infections. The risk of HZ was increased with anifrolumab versus placebo (6.1% vs 1.3%, respectively; EAIR risk difference (95% CI) 5.4 (2.8 to 8.4)); most HZ events were mild or moderate, cutaneous and resolved without treatment discontinuation. Serious infections occurred in 4.8% and 5.6% of patients receiving anifrolumab and placebo, respectively.

Conclusions In this pooled analysis of 925 patients with moderate to severe SLE, monthly intravenous anifrolumab 300 mg was generally well tolerated over 52 weeks with a manageable safety profile.

Anifrolumab was associated with an increased incidence of herpes zoster and respiratory tract infections and a lower reported rate of SLE worsening.

INTRODUCTION

SLE is a chronic, multisystem autoimmune disease associated with substantial morbidity and mortality.1,2 Compared with the general population, studies of patients with SLE also indicate 1.6-fold to 7.8-fold higher rates of several comorbidities, including infections/pneumonia, malignancy, cardiovascular (CV) mortality, ischaemic stroke, myocardial infarction, depression and suicidality.3-11 Standard-of-care (SOC) therapies for SLE, such as antimalarials, immunosuppressants and glucocorticoids are associated with deleterious effects that include retinopathy, CV disease, osteoporosis, cataracts, metabolic abnormalities and increased risk of infections.12-14

Anifrolumab is a human monoclonal antibody that binds the type I interferon (IFN) receptor subunit 1 (IFNAR1). This results in blockade of receptor-mediated type I IFN signalling and subsequent inhibition of
IFN-responsive gene expression and downstream inflammatory and immunologic sequelae. Potential safety concerns related to IFNAR blockade include those associated with immunomodulation, such as opportunistic infections, viral infections (including reactivation) and malignancy. Protein-based infusions also pose risks of hypersensitivity reactions and other infusion-related reactions, independent of the drug’s mechanism of action.

Anifrolumab has been studied for the treatment of adults with moderate to severe SLE in three randomised, double-blind, placebo-controlled, 52-week trials: the MUSE (NCT01438489) phase II trial and the TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) phase III trials. In all three studies, monthly intravenous anifrolumab 300 mg was associated with increased rates of response compared with placebo in British Isles Lupus Assessment Group-based Composite Lupus Assessment response rates at week 52. A consistent benefit was also observed with anifrolumab across a range of other clinically significant efficacy endpoints, including sustained glucocorticoid dosage reduction, reduction in severity of skin disease and reduction in flares.

Understanding the safety profile of anifrolumab and its impact on SLE comorbidities is essential for evaluation of its potential utilisation in the SLE treatment paradigm. Therefore, extensive safety monitoring and evaluation was incorporated into the design of the MUSE, TULIP-1 and TULIP-2 studies (details provided in online supplemental appendix).

The aim of this analysis was to evaluate the safety and tolerability of anifrolumab 300 mg intravenous every 4 weeks relative to placebo, using data pooled from three similarly designed trials (although with differing primary endpoints) to provide more precise estimates of treatment effect on safety than in the individual trials. These trials encompass a population representative of the SLE population with moderate to severe disease despite SOC therapy who are generally seen in clinical practice, with the exception of exclusions (eg, chronic infections, hepatitis and immunodeficiency) to minimise confounding of the safety evaluation.

METHODS

Study design and patients

The detailed methods for each study have been previously reported. MUSE, TULIP-1 and TULIP-2 were randomised, double-blind, 52-week trials that each included evaluation of anifrolumab 300 mg (intravenous every 4 weeks for 48 weeks) or placebo, in patients with moderate to severe SLE despite SOC treatment. MUSE and TULIP-1 also included a higher (1000 mg) and lower (150 mg) dose, respectively. Data from patients who received anifrolumab 300 mg intravenous monthly or placebo in MUSE, TULIP-1 and TULIP-2 were pooled. Because of differences in data collection between MUSE and TULIP, some pooled analyses only included data from the anifrolumab 300 mg arms in TULIP-1 and TULIP-2 (details provided in online supplemental appendix).

The extensive safety evaluation mechanisms incorporated into the anifrolumab clinical development programme included a data safety monitoring board in all three clinical trials (MUSE, TULIP-1 and TULIP-2), as well as the following in TULIP-1 and TULIP-2: Cardiovascular Event Adjudication Committee, Columbia Suicide Severity Rating Scale (C-SSRS) at every visit and Personal Health Questionnaire Depression Scale-8 (PHQ-8) at day 1 and weeks 12, 24, 36 and 52. Further details are provided in the online supplemental appendix.

Safety evaluations and statistical analysis

Safety endpoints analysed from all three studies included percentages and exposure-adjusted incidence rates (EAIRs) of patients receiving placebo or anifrolumab 300 mg who experienced any adverse events (AEs), serious AEs (SAEs), AEs leading to discontinuation of investigational product and AEs of special interest (AESIs) (details provided in online supplemental appendix methods and table S1). A patient with an event that met the criteria for more than one AE category was counted once in each category. Patients with multiple events in the same category are counted only once in that category.

The safety analysis set comprised all patients who received ≥1 dose of anifrolumab or placebo, and patients were analysed according to the treatment they received. Details of the statistical analysis are provided in the supplementary appendix.

RESULTS

Study population

In this integrated safety analysis, 459 and 466 patients received ≥1 dose of anifrolumab 300 mg or placebo, respectively, and comprise the safety analysis set. Additionally, 93 patients received ≥1 dose of anifrolumab 150 mg in TULIP-1 and 105 patients received anifrolumab 1000 mg in MUSE. The latter group included one patient assigned to placebo who erroneously received one dose of anifrolumab 1000 mg.

Baseline demographics, SLE disease severity, SLE treatment and prevalence of CV risk factors and CV disease were similar between patients receiving anifrolumab 300 mg and placebo (online supplemental appendix table S2 and S3). Most patients were female (~93% in both treatment groups) and were predominantly white (59% and 61% in the anifrolumab and placebo groups, respectively), with a mean age of 41 years. African-American patients comprised 14% and 13% of the anifrolumab and placebo groups, respectively, and Asian patients comprised approximately 10% of patients in both treatment groups. Approximately 28% of patients in both treatment groups were of Hispanic or Latino ethnicity. At baseline in pooled TULIP trials data, 80.8% and 83.0% of patients in the anifrolumab 300 mg and placebo groups, respectively, were receiving glucocorticoids, with
approximately half in each treatment group receiving prednisone ≥10 mg/day or equivalent (online supplemental appendix table S3). In both treatment groups, approximately 70% were receiving antimalarials and approximately half of the patients were receiving immunosuppressants including azathioprine, methotrexate, mycophenolate and mizoribine (online supplemental appendix table S3). SLE medication use at baseline in the MUSE trial was similar to that in the TULIP trials (online supplemental appendix table S3).

In all three studies, non-SLE medications taken during the 52-week studies were similar across treatment groups; the most common included paracetamol, omeprazole and folic acid. In TULIP-1 and TULIP-2, where this information was available, the most commonly reported comorbidities at baseline were hypertension (30.7%), gastro-oesophageal reflux disease (15.7%), depression (15.6%), insomnia (14.2%), anxiety (11.7%), hypothyroidism (11.0%), Raynaud’s phenomenon (10.7%), fibromyalgia (10.3%), secondary Sjögren’s syndrome (10.2%) and migraine (10.1%).

Baseline CV risk factors in all three studies combined are listed in online supplemental appendix table S2. The percentages of patients with diabetes or hypertension at baseline were 5.7% and 33.8%, respectively, among patients receiving anifrolumab 300 mg, and 3.6% and 28.8% respectively, among patients receiving placebo. In the pooled TULIP trials, percentages of patients with a history of CV disease at baseline among anifrolumab treated and placebo groups, respectively, were: acute myocardial infarction (0% and 1.4%), unstable angina (0% and 0.3%), coronary revascularisation (0.3% and 0.8%) and heart failure (1.1% and 0.5%).

Fewer patients in the anifrolumab 300 mg group prematurely discontinued treatment compared with patients who discontinued placebo (16.1% vs 26.0%). This held true for each of the most common reasons for discontinuation, including withdrawal by patient (5.4% vs 9.0%), AE (4.4% vs 6.4%) and lack of efficacy (1.1% vs 4.5%). Time to discontinuation for patients receiving anifrolumab and placebo is shown in online supplemental appendix figure S1). More patients in the anifrolumab 300 mg group were exposed to at least 48 weeks of treatment compared with the placebo group (84.3% vs 75.3%), and total patient-years of exposure was slightly greater (419.4 and 403.0 years, respectively).

### Adverse events

The percentage of patients with ≥1 AE during study duration was greater in the anifrolumab 300 mg group (86.9% (399/459)) than in the placebo group (79.4% (370/466)) (table 1). Most AEs were mild or moderate in intensity (36.6% and 41.2%, respectively, among patients receiving anifrolumab, and 38.4% and 33.0%, respectively, among patients receiving placebo. Adverse events were reported per 100 patient-years and calculated as the number of patients with an event/sum of time at risk in days (365.25×100). AEs were coded by MedDRA V.22.1. An AE during intervention period was defined as an AE with a date of onset on or after the day of the first dose of anifrolumab or placebo and on or before the day of the last dose of anifrolumab or placebo plus 28 days. AEIR was reported per 100 patient-years and calculated as the number of patients with an event/sum of time at risk in days (365.25×100). AEs were coded by MedDRA V.22.1. An AE during intervention period was defined as an AE with a date of onset on or after the day of the first dose of anifrolumab or placebo and on or before the day of the last dose of anifrolumab or placebo plus 28 days.

### Table 1 AEs in patients during treatment in pooled MUSE, TULIP-1 and TULIP-2 data

| Event                                      | Anifrolumab 300 mg (n=459) | Placebo (n=466) | EAIR risk difference (anifrolumab 300 mg – placebo) (95% CI) |
|--------------------------------------------|-----------------------------|-----------------|---------------------------------------------------------------|
| Any AE*                                    | 399 (86.9)                  | 370 (79.4)      | NR                                                            |
| SAE                                        | 54 (11.8)                   | 78 (16.7)       | 20.7 (−7.2 to 12.5)                                           |
| Death                                      | 2 (0.4)                     | 0               | 0.5 (−0.5 to 1.7)                                            |
| DAE                                        | 19 (4.1)                    | 24 (5.2)        | 6.0 (−1.4 to 4.7)                                            |
| AEsI†‡                                     | 61 (13.3)                   | 47 (10.1)       | 12.2 (−3.1 to 8.2)                                           |
| Non-opportunistic serious infections       | 22 (4.8)                    | 26 (5.6)        | 6.6 (−1.3 to 4.7)                                            |
| Opportunistic infections                   | 1 (0.2)                     | 1 (0.2)         | 0.0 (−1.2 to 1.1)                                            |
| Anaphylaxis                                | 0                           | 0               | 0                                                             |
| Malignancy                                 | 3 (0.7)                     | 3 (0.6)         | 0.7 (−1.5 to 1.4)                                            |
| Herpes zoster                              | 28 (6.1)                    | 6 (1.3)         | 1.5 (5.4 to 2.8)                                             |
| Active TB                                  | 0                           | 0               | 0                                                             |
| Latent TB§†                                 | 4 (0.9)                     | 1 (0.2)         | 0.2 (0.7 to 0.2)                                             |
| Influenza                                  | 12 (2.6)                    | 9 (1.9)         | 2.3 (0.6 to 3.7)                                             |
| Non-SLE-related vasculitis                 | 0                           | 0               | 0.5 (−0.8 to 1.8)                                            |
| Major adverse cardiovascular event         | 1 (0.2)                     | 3 (0.6)         | 0.7 (−0.5 to 1.8)                                            |

EAIR was reported per 100 patient-years and calculated as the number of patients with an event/sum of time at risk in days (365.25×100).

*AEs were coded by MedDRA V.22.1. An AE during intervention period was defined as an AE with a date of onset on or after the day of the first dose of anifrolumab or placebo and on or before the day of the last dose of anifrolumab or placebo plus 28 days.

†Hypersensitivity was included as an AESI in MUSE but not in the TULIP trials and is not included in this table.

‡AEIs differed from the individual MUSE and TULIP trials and were identified using standardised MedDRA queries and custom preferred term groupings.

§Patients with latent TB (not active TB) were interferon gamma release assay positive without radiographic or clinical manifestations of active TB.

AE, adverse event; AESI, AE of special interest; DAE, AE leading to discontinuation of investigational product; EAIR, exposure-adjusted incidence rate; MedDRA, Medical Dictionary for Regulatory Activities; NR, not reported; SAE, serious AE; TB, tuberculosis.
patients receiving placebo). In the anifrolumab group, the most frequently reported AEs were nasopharyngitis, upper respiratory tract infection, urinary tract infection, bronchitis and infusion-related reaction (table 2). AEs that were more common in the anifrolumab group than in the placebo group (ie, ≥5% difference, or ≥5% incidence in the anifrolumab group and at least twice the reported rate of the placebo group) were nasopharyngitis, upper respiratory tract infection, bronchitis, and herpes zoster (HZ). No clinically meaningful differences were observed in the frequency or pattern of AEs for patients receiving anifrolumab and classified at baseline as interferon gene signature (IFNGS) high (76.2% with any AE above the reporting threshold of 2% (227/298)) versus IFNGS low (77.4% (48/62)) in pooled data from TULIP-1 and TULIP-2.

A total of 54/459 patients (11.8%) receiving anifrolumab 300 mg and 78/466 (16.7%) receiving placebo experienced ≥1 SAE during treatment (table 1). SAEs included infections (anifrolumab: 22 (4.8%) and placebo: 26 (5.6%), of which pneumonia accounted for eight (1.7%) and nine (1.9%), respectively), as well as worsening of SLE that met criteria for an SAE (7 (1.5%) and 14 (3.0%), respectively).

Table 2: AEs reported by ≥2% of patients in pooled MUSE, TULIP-1 and TULIP-2 data

| AE* | Anifrolumab 300 mg (n=459) | Placebo (n=466) |
|-----|--------------------------|------------------|
|     | n (%)                    | n (%)            |
| Nasopharyngitis† | 75 (16.3) | 44 (9.4) |
| Upper respiratory tract infection† | 71 (15.5) | 45 (9.7) |
| Urinary tract infection | 55 (12.0) | 63 (13.5) |
| Bronchitis† | 45 (9.8) | 20 (4.3) |
| Infusion-related reaction | 43 (9.4) | 33 (7.1) |
| Headache | 37 (8.1) | 45 (9.7) |
| Herpes zoster† | 28 (6.1) | 6 (1.3) |
| Back pain | 24 (5.2) | 20 (4.3) |
| Sinusitis | 24 (5.2) | 24 (5.2) |
| Cough | 23 (5.0) | 15 (3.2) |
| Arthralgia | 22 (4.8) | 9 (1.9) |
| Pharyngitis | 21 (4.6) | 17 (3.6) |
| Vomiting | 18 (3.9) | 12 (2.6) |
| Nausea | 17 (3.7) | 25 (5.4) |
| Oral herpes | 17 (3.7) | 12 (2.6) |
| Pneumonia | 15 (3.3) | 13 (2.8) |
| Diarrhoea | 14 (3.1) | 25 (5.4) |
| Respiratory tract infection | 14 (3.1) | 2 (0.4) |
| Depression | 13 (2.8) | 8 (1.7) |
| Gastroenteritis | 13 (2.8) | 14 (3.0) |
| Hypersensitivity | 13 (2.8) | 3 (0.6) |
| Influenza | 12 (2.6) | 9 (1.9) |
| Gastroenteritis (viral) | 11 (2.4) | 7 (1.5) |
| Gastro-oesophageal reflux disease | 11 (2.4) | 12 (2.6) |
| Pain in extremity | 11 (2.4) | 3 (0.6) |
| Anxiety | 10 (2.2) | 8 (1.7) |
| Dizziness | 10 (2.2) | 12 (2.6) |
| Fatigue | 10 (2.2) | 9 (1.9) |
| Peripheral oedema | 10 (2.2) | 4 (0.9) |
| SLE | 10 (2.2) | 14 (3.0) |
| Insomnia | 9 (2.0) | 19 (4.1) |

EAIR was reported per 100 patient-years and calculated as the number of patients with an event/ [sum of time at risk in days/ (365.25×100)]. AEs were coded by MedDRA V.22.1. An AE during the intervention period was defined as an AE with a date of onset on or after the day of the first dose of anifrolumab or placebo and on or before the day of the last dose of anifrolumab or placebo plus 28 days. AEs were more common in the anifrolumab 300 mg group than in the placebo group (ie, ≥5% difference, or ≥5% incidence in the anifrolumab group and at least twice the reported rate of the placebo group).

AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities.
Discontinuations due to AEs and deaths

AEs led to discontinuation of investigational product in 19 (4.1%) patients receiving anifrolumab 300mg and 24 (5.2%) receiving placebo. During the three 52-week controlled studies, there were two deaths among patients treated with anifrolumab 300mg, both due to pneumonia, with one case considered by the investigator to be related to the investigational product (day 221) and one (day 64) considered unrelated to treatment, and one death in a patient receiving placebo (due to colitis (day 34), considered unrelated to treatment), during the follow-up period.

AEs of special interest

AEIs that occurred in patients receiving placebo and anifrolumab 300mg are summarised in table 1.

Infections

Infections overall during treatment, as categorised using the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class infections and infestations were reported in a greater percentage of patients in the anifrolumab 300mg group than in the placebo group (69.7% (320/459) vs 55.4% (258/466)). Most infections in both treatment groups were mild or moderate in intensity, were not classified as SAEs and did not result in discontinuation of anifrolumab or placebo. The difference between the reported rates of infection was driven by differences in the incidence of mild and moderate infections involving the respiratory tract, excluding pneumonia (which was similar between both treatment groups) and separately by HZ. Non-opportunistic serious infection rates were similar and occurred in 4.8% and 5.6% of patients receiving anifrolumab and placebo, respectively (table 1).

Three opportunistic infections were reported: one anifrolumab patient had a non-serious AE with preferred term (PT) mycobacterium avium complex infection that led to treatment discontinuation, and two placebo patients had opportunistic infections (PT oropharyngeal candidiasis, PT meningitis cryptococcal). The rate of influenza was similar between groups, and no cases of active TB were reported.

Herpes zoster

Patients in the anifrolumab 300mg group had an increased risk of HZ compared with patients in the placebo group (6.1% and 1.3%, respectively; EAIR risk difference (95% CI) 5.4 (2.8 to 8.4)) (table 3). In TULIP-1, HZ occurred in 5.4% and 1.6% of patients receiving anifrolumab 150mg (n=93) and placebo (n=184), respectively. The rate of HZ was greater for patients receiving anifrolumab 1000mg (n=105) in MUSE, 8.6% versus 1.0% for placebo (n=101) (online supplemental appendix table S4).

Across the placebo and anifrolumab 300mg groups from all three studies, in the 34 patients with HZ AEs, 32 patients had mild or moderate cases and two patients had a severe case (table 3); most cases were cutaneous. Two patients treated with anifrolumab 300mg had HZ SAEs. One patient receiving anifrolumab 300mg discontinued treatment due to transverse myelitis with a positive PCR test for HZ in the cerebrospinal fluid and no cutaneous presentation. This patient responded to antiviral and high-dose glucocorticoid treatment and fully recovered without sequelae. The patient had received two doses of anifrolumab and was also receiving concomitant treatment with immunosuppressants. This AE was assessed by the investigator to be unrelated to treatment. All patients in the anifrolumab 300mg group and four of six patients in the placebo group with HZ AEs received antiviral

Table 3 Herpes zoster events in patients during treatment with anifrolumab 300mg versus placebo in pooled MUSE, TULIP-1 and TULIP-2 data

|                      | Anifrolumab 300mg (n=459) | Placebo (n=466) | EAIR (per 100 PY) | EAIR (per 100 PY) |
|----------------------|---------------------------|-----------------|------------------|------------------|
|                      | n (%)                     | n (%)           |                  |                  |
| Any AE               | 28 (6.1)                  | 6 (1.3)         | 6.9              | 6.9              |
| Any AE with outcome of death | 0                      | 0               | 0                | 0                |
| Any SAE              | 2 (0.4)                   | 0.5             | 0.5              | 0.5              |
| Any DAE              | 2 (0.4)                   | 0.5             | 0.5              | 0.5              |

EAIR was reported per 100 PY and defined as the number of patients with the specific event divided by the total exposure time in years and then multiplied by 100. The exposure time was defined as the time from the date of first administration of investigational product to the date of first event, death, end of treatment plus 28 days or end of study, whatever came first. AE, adverse event; DAE, AE leading to discontinuation of investigational product; EAIR, exposure-adjusted incidence rate; PY, patient-years; SAE, serious AE.
treatment and all cases resolved. Of the 34 patients with HZ AEs, 32 continued in the study; AEs leading to discontinuation were non-serious, with the exception of the transverse myelitis case. Among patients for whom data regarding dermatome involvement were available (TULIP-1 and TULIP-2), four cases involved three or more dermatomes (anifrolumab 300 mg: n=3; placebo: n=1). Time to first onset of HZ was slightly shorter in the anifrolumab 300 mg than in the placebo group (figure 1). Among patients for whom data regarding history of HZ prior to study enrolment were available (TULIP-1 and TULIP-2) and in whom HZ occurred during treatment, 4 of the 23 patients receiving anifrolumab 300 mg and one of the five patients receiving placebo had a history of HZ prior to study enrolment.

Subgroup analyses of pooled data available from TULIP-1 and TULIP-2 did not suggest any clear trends in HZ cases by demographics, baseline disease characteristics or SLE-related medication use (figure 2). However, the rate of HZ events was greater in the anifrolumab 300 mg group among patients who received immunosuppressant (9.8%, n=17) than those who did not receive immunosuppressant (3.2%, n=6).

Malignancy
Malignancies, including nonmelanoma skin cancers, were reported in six patients (1.3% (6/459)) receiving anifrolumab 300 mg and three patients (0.6% (3/466)) receiving placebo. Excluding non-melanoma skin cancers, malignancies were reported in three patients (0.65%) receiving anifrolumab (two invasive ductal breast carcinoma and one B cell lymphoma, the latter existing before first dose of anifrolumab) and in three patients (0.6%) receiving placebo (one carcinoid tumour, one squamous cell carcinoma of the cervix and one uterine cancer).

Other AESIs
Among patients in TULIP-1 and TULIP-2, adjudicated major adverse cardiovascular events were reported in one patient receiving anifrolumab 300 mg (non-fatal myocardial infarction) and in no patients in the placebo group. In the MUSE study, in which events were not adjudicated, no CV events were reported among patients receiving anifrolumab 300 mg (n=99), and three were reported among patients receiving placebo (two ischaemic strokes and one cerebral infarction). Non-SLE-related vasculitis was not observed in any anifrolumab-treated patients.

Anaphylaxis, hypersensitivity and infusion-related reactions
Hypersensitivity reactions were reported by 2.6% (12/459) and 0.6% (3/466) of patients receiving anifrolumab 300 mg and placebo, respectively. These events were predominantly mild or moderate in intensity and occurred during the first 12 weeks (ie, first three to four infusions). One patient receiving anifrolumab 300 mg experienced a serious hypersensitivity event, which was treated, and anifrolumab treatment was continued. Anaphylaxis was not reported among any patients receiving anifrolumab 300 mg but was reported in one patient receiving anifrolumab 150 mg; this patient was treated, the condition resolved and the patient discontinued study treatment.

Infusion-related reactions occurred in 43/459 patients (9.4%) receiving anifrolumab 300 mg and 33/466 (7.1%)
receiving placebo. All were mild or moderate in intensity, and most occurred in the first 24 weeks of treatment. In data available only for the pooled TULIP trials, the most common infusion-related reaction symptoms among patients receiving anifrolumab were headache, nausea, vomiting and fatigue.

**Other safety events**
In pooled data available only for the TULIP trials, there was no evidence of increased risk for suicidality per assessment with the C-SSRS or reported AEs, or for depression based on PHQ-8 scores and the standardised MedDRA queries depression (excluding suicide and self-injury) narrow search (details provided in online supplemental results).

In both TULIP-1 and TULIP-2, fewer patients had Cushingoid features at week 52 compared with baseline across all treatment groups. In TULIP-1, most notable decreases from baseline observed with anifrolumab versus placebo were for features of moon face (from 17.8% to 9.4% vs 18.5% to 14.1%), easy bruising (21.1% to 15.0% vs 19.0% to 13.6%) and acne (7.2% to 1.1% vs 4.9% to 1.6%). In TULIP-2, the most notable decreases from baseline observed with anifrolumab versus placebo were for

---

**Figure 2** Adjusted difference in cumulative proportions of patients with herpes zoster events in subgroups of patients treated with anifrolumab 300 mg versus placebo in pooled TULIP-1 and TULIP-2 data. ADA, antidrug antibody; BMI, body mass index; IFNGS, interferon gene signature; GC, glucocorticoid; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000. Immunosuppressant use is defined at baseline. Left and right bars indicate the lower and upper limit of the 95% CI. Numbers under ‘(%)’ indicate the cumulative proportion.
features of moon face (13.9% to 7.2% vs 17.6% to 9.3%) and hirsutism (5.6% to 0.6% vs 2.2% to 1.1%).

Among 837 patients with SLE exposed to anifrolumab during the anifrolumab SLE clinical programme, there were 20 patients with one or more pregnancies despite the requirement to use contraception during study participation. No drug-associated congenital anomalies or drug-associated AEs were observed among these pregnancies (details provided in online supplemental appendix).

**Laboratory, electrocardiogram and vital sign results**

In the integrated analysis of data from TULIP-1 and TULIP-2, mean haematology and clinical chemistry values were generally similar between patients receiving anifrolumab 300 mg and placebo at baseline and at week 52 (online supplemental appendix table S5), and no clinically meaningful differences were noted between treatment groups over time.

No differences in mean blood pressure values or heart rate were noted between anifrolumab 300 mg and placebo groups, nor clinically meaningful trends in change from baseline values at 52 weeks. No clinically meaningful shifts in ECG parameters from normal to abnormal were reported.

In TULIP-1 and TULIP-2, there were no clinically important differences among treatment groups in mean changes from baseline to week 52 in body weight (TULIP-1: anifrolumab +1.43 kg, placebo +0.71 kg; TULIP-2: anifrolumab +1.54 kg, placebo +0.35 kg).

**Immunogenicity**

Anifrolumab administered as an intravenous infusion was associated with low levels of antidrug antibodies (ADAs) in patients with moderate to severe SLE. Among patients in whom ADAs were detected, there was no clinically relevant impact on pharmacokinetics, pharmacodynamics or safety. The percentage of patients ADA positive at any point and persistently ADA positive in pooled data from TULIP-1 and TULIP-2 was 7.0% and 1.2%, respectively, for anifrolumab 300 mg and 9.6% and 2.0%, respectively, for placebo (online supplemental appendix table S6). The screening and confirmatory cut-point factors used in the assay to detect ADAs were determined from 419 baseline SLE serum samples from patients enrolled in the TULIP-1 study. Drug tolerance assessments evaluated the effect of anifrolumab on the detection of ADAs. These data showed that 125 ng/mL of affinity purified polyclonal anti-anifrolumab idiotype antibody could be detected in the presence of 25 pg/mL of drug indicating that the ADA assay was sensitive and drug tolerant making false negative results unlikely. However, the selection of the low cut-points made detection of false positive results possible. The number, temporal response, titre, and all other categories of ADA assessments conducted never favoured anifrolumab (as compared with placebo) supporting the conclusion that anifrolumab is very poorly immunogenic when administered intravenously to patients with SLE.

**DISCUSSION**

Morbidity in patients with SLE results from the combined deleterious effects of disease activity and treatment. Most patients with SLE require combination treatment and many of the agents currently recommended have either multiple, or non-specific, mechanisms of action, making AEs both more likely and less predictable. The potential introduction of a new immune-targeting drug as an add-on therapy for SLE requires comprehensive assessment of safety for its risk–benefit, and therefore its place in the therapeutic armamentarium, to be determined. Anifrolumab, which specifically targets the common receptor for all type I IFN signalling proteins, has been shown to suppress IFN gene signatures and deliver efficacy in active SLE across three phase II and III trials. Although safety data for each of these studies have been reported separately, the integrated safety analysis reported here allows for assessment of the rate and severity of both common and less common AEs.

These analyses were focused on reporting of the safety in the anifrolumab 300 mg group because this is the recommended dose for anifrolumab. The anifrolumab 150 mg dose in TULIP-1 had suboptimal efficacy and pharmacokinetics, and the 1000 mg dose in MUSE was associated with a higher rate of HZ. These analyses of pooled data indicate that anifrolumab 300 mg was generally well tolerated by patients with SLE. The most commonly reported AEs were mild to moderate in severity and included nasopharyngitis, upper respiratory tract infection, urinary tract infection, bronchitis and infusion-related reactions. AEs leading to discontinuation of investigational product were infrequent and were balanced between the groups. During the three 52-week studies, there were three deaths among patients treated with anifrolumab (two with 300 mg and one with anifrolumab 1000 mg) and one death in a patient receiving placebo. There was a lower reported rate of SAEs in patients receiving anifrolumab versus placebo. Lupus affects multiple organs, and anifrolumab has demonstrated efficacy for disease activity and reduction of flares, which may explain the lower rate of SAEs in the anifrolumab group of these trials. Among SAEs, infections including pneumonia were most common and were similar between anifrolumab (4.8%) and placebo (5.6%) groups. The rate of worsening of SLE as an SAE was greater in patients receiving placebo (3.0% vs 1.5% with anifrolumab), concordant with the numerically lower flare rates observed with anifrolumab 300 mg versus placebo in all three studies.

Compared with patients receiving placebo, more patients in the anifrolumab 300 mg group experienced an AE in the System Organ Class of infections and infestations (69.7% vs 55.4%). The percentages of infections in treatment and placebo groups in patients with SLE were each comparable with those reported in clinical trials of the monoclonal antibodies to B cell activating factor tabalumab and belimumab and for epratuzumab, a monoclonal antibody to CD22. Most infections in both anifrolumab and placebo groups were mild or moderate, consistent with the low immunogenicity of anifrolumab.
moderate in intensity, were not classified as SAEs and did not result in discontinuation of investigational product. The difference in rates was driven by differences in the incidence rates of mild and moderate respiratory tract infections (excluding pneumonia) and by HZ. Overall, the rate of serious infections was low with anifrolumab and similar to that in the placebo group.

There was an increased risk of HZ with anifrolumab versus placebo (6.1% and 1.3%, respectively; EAIR risk difference 5.4). However, HZ event characteristics, including duration and severity, were similar between treatment groups. Most HZ events were mild or moderate, cutaneous and resolved with antiviral treatment and without treatment discontinuation. One patient had an SAE of transverse myelitis during the MUSE study.18 The patient had a positive PCR test for HZ in spinal fluid, there were no cutaneous manifestations of HZ, and they responded following treatment with both antivirals and glucocorticoids. We cannot determine whether the underlying cause was HZ or a manifestation of SLE. This transverse myelitis case was not considered by investigators to be related to treatment, and the patient made a full recovery with no observed long-term disability. This analysis did not reveal any patient or treatment characteristics predictive of HZ reactivation, although these were numerically more common in patients receiving immunosuppressants as part of SOC therapy. As patients with SLE are known to have an increased baseline risk of HZ reactivation, it may be valuable to evaluate strategies to vaccinate this patient population prior to receipt of immunosuppressive therapies in both the clinic and clinical trial setting.26 This strategy is supported by recently updated EULAR guidelines on vaccination in autoimmune inflammatory rheumatic diseases, which recommend considering HZ vaccination in patients considered high risk.27

Infusion-related reactions were uncommon, although the rate of AEs reported as hypersensitivity and infusion-related reactions was greater with anifrolumab-treated patients (2.6% and 9.4%, respectively) than placebo (0.6% and 7.1%, respectively); most occurred early and were mild or moderate in intensity. Hypersensitivity SAE was observed in one patient receiving anifrolumab 300 mg, and one patient receiving anifrolumab 150 mg had an anaphylactic reaction. The rates of hypersensitivity/infusion-related reactions are comparable with those reported in patients with SLE in 52-week phase III trials of tabalumab and belimumab.24 25

Exposure to anifrolumab, a fully humanised monoclonal antibody, administered as an intravenous infusion to patients with SLE was minimally immunogenic. Among patients in whom ADAs were detected, there was no clinically relevant impact on pharmacokinetics, pharmacodynamics or safety. The subgroups of patients positive for ADA were small; thus, these results should be interpreted with caution. The selection of low assay cut-points also made detection of false positive results possible. The number, temporal response, titre and all other categories of ADA assessments conducted never favoured anifrolumab (as compared with placebo) supporting the conclusion that anifrolumab is very poorly immunogenic when administered intravenously to patients with SLE.

In patients treated with anifrolumab, flares of SLE as AEs were less common, despite protocol-determined glucocorticoid tapering in all three studies. The harmful effects of glucocorticoids, both in general and in the setting of SLE, are well known and include increased risk of irreversible organ damage and susceptibility to infection.18 20 Furthermore, fewer patients had Cushingoid features at week 52 compared with baseline across all treatment groups, with notable decreases with anifrolumab versus placebo. Therefore, the sustained glucocorticoid reduction achieved with anifrolumab represents a potential safety benefit.

The safety profile in these trials of anifrolumab is broadly comparable with that reported in phase III programmes of other treatments for patients with SLE.25–27 The patient populations selected in the MUSE, TULIP-1 and TULIP-2 trials were intended to reflect the real-world population of patients with moderate to severe SLE despite SOC therapy; however, certain exclusion criteria were necessary to minimise confounding in safety evaluations. Therefore, the future reporting of real-world safety experience with anifrolumab treatment in patients with SLE will be important.

These analyses have several limitations, including a duration of only 1 year. However, 218 patients who completed MUSE were enrolled in a long-term extension study, 139 of who completed 3 years of treatment. This long-term observational study reported that the rate and patterns of SAEs and AEs of special interest over the 3 years were consistent with those reported for 1 year of treatment in the primary MUSE study.30 A further placebo-controlled long-term observational extension study of patients enrolled in the TULIP-1 and TULIP-2 trials is ongoing and will provide additional long-term safety data. Another limitation was that patients with severe renal lupus and neuropsychiatric disorders were excluded from the TULIP-1, TULIP-2 and MUSE trials, and therefore, the efficacy and safety of anifrolumab in these patient subgroups still needs to be studied. A phase II study of anifrolumab in patients with lupus nephritis is ongoing.

The decision to use any medication requires a patient-focused shared decision-making process balancing benefit and risk. The current analysis shows that anifrolumab 300 mg intravenous monthly had an acceptable safety profile during 52 weeks of treatment in adult patients who had moderate to severe SLE despite SOC therapy. Taken together with the previously reported efficacy based on global disease activity improvement, glucocorticoid dosage tapering and SLE flare reduction,18–20 anifrolumab has a positive benefit–risk profile and is a potential new treatment option for a disease with few therapeutic options.
Acknowledgements The authors would like to thank Claire Morgan, MD, Lisa Beth Ferstenberg, MD, Lijin Zhang, PhD, Thor Hupka, MD, Pranita Kabadi, PhD and Marta Pujol, PhD for their assistance in these analyses. The authors would also like to thank the patients, study sites and investigators who participated in these clinical trials and also appreciate all members of the global academic steering committee and local steering committees. Writing and editing assistance was provided by Angela Cimmino, PharmD, and Luke Burke, PhD, of JK Associates Inc, a Fishawack Health Company. This support was funded by AstraZeneca.

Contributors All authors contributed to the development of the manuscript, including interpretation of results, substantive review of drafts, and approval of the final draft for submission. GA led the statistical analyses.

Funding This study was supported by AstraZeneca (Gaithersburg, Maryland, USA).

Competing interests RT, GA, LP, MAM and RKN are employees of AstraZeneca. RAF has received grant/research support and consulting fees from AstraZeneca. EM has received grant support from, was a consultant for and was a speaker at a speaker bureau for AstraZeneca; received grant support and consulting fees from AbbVie, BMS, Eli Lilly, GSK, Janssen, Merck Serono and UCB; received grant support from BMS, and received consulting fees from Amgen, Biogen, CSL Inc, Neovacs and Wolf Biotherapeutics.

Patient consent for publication Not required.

Ethics approval The MUSE, TULIP-1 and TULIP-2 trials were conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Good Clinical Practice, and all patients provided written informed consent in accordance with local requirements.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmaccm.com/ST/Submission/Disclosure.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
1 Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaboratingclinics (SLICC) inception cohort. *Ann Rheum Dis* 2015;74:1706–13.
2 Jorge AM, Lu N, Zhang Y, et al. Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). *Rheumatology* 2018;57:337–44.
3 Arkema EV, Svenningsson E, Von Euler M, et al. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. *Ann Rheum Dis* 2017;76:1544–9.
4 Choi MY, Flood K, Bernatsky S, et al. A review on SLE and malignancy. *Best Pract Res Clin Rheumatol* 2017;31:373–96.
5 Hermansen M-L, Lindhardsen J, Torp-Pedersen C, et al. The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study. *Rheumatology* 2017;56:kew475–15.
6 Zhang L, Fu T, Yin R, et al. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. *BMC Psychiatry* 2017;17:77.
7 Tektonidou MG, Wang Z, Das Gupta A, et al. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996-2011. *Arthritis Care Res* 2015;67:1078–85.
8 Georgakini I, Bertias G. Systemic lupus erythematosus in primary care: an update and practical messages for the general practitioner. *Front Med* 2018;5:161.
9 González LA, Alarcón GS. The evolving concept of SLE comorbidities. *Expert Rev Clin Immunol* 2017;13:753–68.
10 Pego-Reis RM, Nicholson L, Pooley N, et al. The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. *Rheumatology* 2021;60:60–72.
11 Yazdany J, Pooley N, Langhammer J, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. *RMD Open* 2020;6:e001247.
12 Al Savah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins lupus cohort. *Lupus Sci Med* 2015;2:e000086.
13 Oglesby A, Shaul AJ, Pokora T, et al. Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review. *Int J Rheumatol* 2013;2013:1–9.
14 Loxpa R, Lants LA, R, et al. Pan-sicoid side effects in systemic lupus erythematosus. *Curr Health Sci J* 2018;44:316–21.
15 Peng L, Oganesyan V, Wu H, et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. *MAbs* 2015;7:428–39.
16 Crow MK, Romboletti, Type 1 interferon in host defense and inflammatory diseases. *Lupus Sci Med* 2019;6:e000336.
17 Akarsu A, Seyer O, Sekerei BE. Hypersensitivity reactions to biologicals: from bench to bedside. *Curr Treat Options Allergy* 2020;7:71–83.
18 Furie R, Kharmashita M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. *Arthritis Rheumatol* 2017;79:367–86.
19 Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. *Lancet Rheumatol* 2019;1:e208–19.
20 Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. *N Engl J Med* 2020;382:211–21.
21 Shankar G, Arkin S, Coccoa L, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. *Aaps J* 2014;16:658–73.
22 Fanourakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019;78:736–45.
23 Clowe MEB, Wallace DJ, Furie RA, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. *Arthritis Rheumatol* 2017;69:562–75.
24 Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabulamab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. *Ann Rheum Dis* 2016;75:332–40.
25 Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. *Lupus* 2013;22:144–54.
26 Mok CC. Herpes zoster vaccination in systemic lupus erythematosus: the current status. *Hum Vac Immunotherapeut* 2019;15:45–8.
27 Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adults with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis* 2020;79:39–52.
28 Apostolopoulos D, Morand EF. It hasn’t gone away: the problem of glucocorticoid use in lupus remains. *Rheumatology* 2017;56:114–22.
29 Apostolopoulos D, Kandane-Glynn S, Louthrenoo W, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. *Lancet Rheumatol* 2020;2:e24–30.
30 Chatham WW, Furie R, Saxena A, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase 2 open-label extension study. *Arthritis Rheumatol* 2020; doi:10.1002/art.41598
SUPPLEMENTARY APPENDIX

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Safety Profile of Anifrolumab in Patients With Active Systemic Lupus Erythematosus: An Integrated Analysis of Phase 2 and 3 Trials
Table of Contents

1. Supplementary Methods ................................................................. 3
   1.1 Safety Monitoring ................................................................. Error! Bookmark not defined.
   1.2 Study Design and Patients .................................................. 3
   1.3 Safety Evaluations ............................................................... 3
   1.4 Statistical Analysis ............................................................... 3
2. Supplementary Results ................................................................. 4
   2.1 Depression and Suicidality .................................................... 4
   2.2 Pregnancy ............................................................................... 4
3. Supplementary Tables ......................................................................... 5
   Table S1. Adverse Events of Special Interest (AESIs) ....................... 5
   Table S2. Baseline Demographics and Disease Characteristics in Pooled MUSE, TULIP-1, and TULIP-2 Data ......................... 6
   Table S3. Baseline SLE Medications in MUSE and in Pooled TULIP-1 and TULIP-2 Data ................................................................. 6
   Table S4. Herpes Zoster Events During Treatment With Anifrolumab 1000 mg vs Placebo in MUSE and Anifrolumab 150 mg vs Placebo in TULIP-1 ......................................................... 8
   Table S5. Selected Laboratory Parameters With Anifrolumab 300 mg in Pooled TULIP-1 and TULIP-2 Data ................................. 9
   Table S6. Anti-drug Antibodies During Treatment in Pooled Data from TULIP-1 and TULIP-2 ......................................................... 10
4. Supplementary Figures ......................................................................... 11
   Figure S1. Time to Discontinuation of Anifrolumab 300 mg vs Placebo in Pooled MUSE, TULIP-1, and TULIP-2 Data ....................... 11
5. References .......................................................................................... 12
1. Supplementary Methods

1.1 Study Design and Patients

In all three studies, randomization was stratified according to SLE Disease Activity Index 2000 (SLEDAI-2K) (<10 or ≥10) at screening, baseline glucocorticoid dosage (<10 mg/day or ≥10 mg/day of prednisone or equivalent), and type I IFN gene signature test result at screening (IFNGS; high or low). All studies were approved by the institutional review board or ethics committee at each participating institution and conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent.

1.2 Safety Evaluations

AEs in the integrated safety analyses were coded according to Medical Dictionary for Regulatory Activities (MedDRA) version 22.1, which was used across studies.

The AESIs for this integrated safety analysis are summarized in table S1. For this integrated analysis, AESIs were identified from the datasets using standardized MedDRA queries (SMQ) and custom preferred term groupings.

The characterization of HZ was further explored, including the use of Kaplan–Meier plots to analyze time to first onset of HZ and time from onset to resolution of first HZ event during treatment.

Suicidal ideation and behavior were assessed in TULIP-1 and TULIP-2 both by Columbia Suicide Severity Rating Scale (C-SSRS), administered at all study visits by a trained rater, and by AEs related to suicidal ideation and behavior identified using a custom MedDRA term list. Depression was assessed in TULIP-1 and TULIP-2 using both the Personal Health Questionnaire Depression Scale-8 (PHQ-8), administered every 3 months, and AEs related to depression identified using the MedDRA SMQ depression (excluding suicide and self-injury) narrow search.

SLE worsening as a safety outcome was evaluated by examining the proportions of patients with an SAE with the preferred term “systemic lupus erythematosus.” This is separate from the BILAG-based flare rate recorded as an efficacy endpoint in all three studies (defined as ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B organ domain scores vs previous visit).[1]

Clinical laboratory evaluations, vital sign measurements, and electrocardiogram (ECG) results were analyzed for data pooled from TULIP-1 and TULIP-2 only. Physical examination results from individual studies were not pooled.

Results are presented for AEs during treatment (defined as events with onset between day of first study treatment dose and day of last study treatment dose plus 28 days). Patients with multiple events in the same category are counted only once in that category. Patients with events in more than one category are counted once in each of those categories. Any AE by intensity was counted once by maximum reported intensity. Throughout each study, an independent data and safety monitoring board reviewed blinded safety data and could access unblinded data upon request.

1.3 Statistical Analysis

AEs were summarized using descriptive statistics. Demographic data and SLE disease characteristics are presented using descriptive statistics for the overall safety analysis set and by treatment group and at risk of an initial occurrence of the event. The safety analysis set consisted of all patients who have received at least one dose of investigational product. Erroneously treated patients (eg, those randomized to receive treatment A but actually given treatment B) are accounted for in the treatment group of the treatment they actually received. A patient who had on one or several occasions received anifrolumab was classified in the respective anifrolumab group. A patient who received different anifrolumab doses was classified in the higher dose regimen. Duration of exposure in days is summarized using descriptive statistics and as a Kaplan–Meier plot by treatment group.

Time to discontinuation of investigational product is presented as a Kaplan–Meier plot including the number of patients at risk (still receiving investigational product).

Reported event rates were based on EAIRs, which are defined as the number of patients with a specific event divided by the total exposure time among the patients in the treatment group. The EAIRs are reported as events per 100 patient-years and derived by number of patients with an event/ [sum of time at risk in days/(365.25×100)]. Comparisons between treatment groups (risk difference) and 95% confidence intervals.
(CIs) were estimated based on the Miettinen and Nurminen method.[2] Adjusted cumulative proportions are presented for HZ and depression AEs based on Cochrane–Mantel–Haenszel weighting.[3]

Values outside the limit of quantification were imputed as having a value equal to that limit in the calculation of summary statistics. Missing data for categorical values were presented as a separate category, and the denominator included missing values as appropriate. For missing AE onset dates, the AE was counted as occurring during treatment unless the date of resolution indicated otherwise. Missing safety data were otherwise not imputed.

Subgroup analyses conducted based on data pooled from TULIP-1 and TULIP-2 only will be reported separately.

2. Supplementary Results

2.1 Depression and Suicidality

In pooled data available only for the TULIP trials, PHQ-8 scores were similar across all treatment groups at baseline, and no clinically meaningful changes from baseline to Week 52 were observed for any treatment group. Small and similar decreases in PHQ-8 scores were observed in all treatment groups from baseline to Week 52.

There were few AEs related to depression as assessed using the MedDRA SMQ depression (excluding suicide and self-injury) narrow search, which were balanced between the treatment groups. Depression was reported in 3.1% (11/360) and 2.5% (9/365) of patients receiving anifrolumab 300 mg and placebo, respectively (adjusted difference in cumulative proportion [95% CI]: 0.6 [–2.2, 3.4]). Mixed anxiety and depression disorder was reported in 0.3% (1/360) and 0% (0/365) of patients receiving anifrolumab 300 mg and placebo, respectively. Depressed mood and persistent depressive disorder were not reported in any patients receiving anifrolumab, but one instance of each was reported in patients receiving placebo.

There was no evidence of increased risk in suicidal ideation or behavior in patients receiving anifrolumab vs placebo as assessed using the C-SSRS in pooled TULIP data. Suicidal ideation or behavior during the screening period was reported in 1.9% (7/360) and 2.5% (9/365) of patients receiving anifrolumab and placebo, respectively, based on the C-SSRS. During the study, suicidal ideation or behavior was reported in 1.4% (5/360) and 2.7% (10/365) of patients receiving anifrolumab and placebo, respectively. Based on reported AEs using the custom MedDRA term list in pooled TULIP data, suicidal ideation or behavior was reported in no patients receiving anifrolumab 300 mg and in two patients receiving placebo (one suicide attempt and one report of suicidal ideation).

2.2 Pregnancy

In the anifrolumab SLE clinical program, among 837 patients with SLE exposed to anifrolumab, there were 20 pregnancies among patients with one or more pregnancies as of the cut-off date of August 1, 2019. Among these pregnancies, no congenital anomalies and no drug-associated AEs were observed. Among patients in the integrated analysis of TULIP-1, TULIP-2, and MUSE, one patient receiving anifrolumab 300 mg experienced pre-eclampsia. In the Phase 2 and Phase 3 extension trials, one patient receiving anifrolumab 300 mg experienced a spontaneous abortion, one experienced a premature delivery, and one experienced a high-risk pregnancy. There were no reports of spontaneous abortions, premature deliveries, high-risk pregnancies or pre-eclampsia among patients receiving placebo in the integrated analysis of TULIP-1, TULIP-2, and MUSE, or in the Phase 2 extension trial. The isolated cases of spontaneous abortion and premature delivery observed among patients receiving anifrolumab are in line with the rates of adverse pregnancy outcomes observed in the SLE patient population. In a meta-analysis of 2751 pregnancies among 1842 patients with SLE, spontaneous abortion occurred in 16.0% of pregnancies and the premature birth rate was 39.4%.[4] Patients had active nephritis during 16.1% of these pregnancies.
3. Supplementary Tables

**Table S1. Adverse Events of Special Interest (AESIs)**

| AESI                        | Summary of AESI identification criteriaa,b,c,d,e,f |
|-----------------------------|---------------------------------------------------|
| Non-opportunistic serious infections | - All SAEs in the SOC infections and infestations, excluding AEs defined as opportunistic infections  
- Was not included as a protocol-specified AESI in MUSE |  
| Opportunistic infections    | - All serious and non-serious AEs with PTs included in a MedDRA custom PT grouping  
- Was not included as a protocol-specified AESI in MUSE |  
| Herpes zoster               | AEs of herpes zoster included serious and non-serious AEs identified by select PTs from the HLT Herpes viral infections. |  
| TB (including latent TB)    | - AEs of TB or latent TB were identified using a custom MedDRA PT grouping (PTs: latent tuberculosis, tuberculosis, and mycobacterium tuberculosis complex test positive)  
- Latent TB was not included as a protocol-specified AESI in MUSE (new and reactivated TB were included as AESIs) |  
| Influenza                   | - AEs with the PT influenza  
- SAEs of influenza were also included in the AESI category non-opportunistic serious infection  
- Was not included as a protocol-specified AESI in MUSE |  
| Anaphylaxis                 | Anaphylaxis case definition based on Sampson et al 2006 criteria[5]  
Custom MedDRA PT grouping (PTs: anaphylactic reaction, anaphylactic shock, anaphylactoid reaction, and anaphylactoid shock) |  
| Malignancy                  | Four SMQs: hematological malignant tumors, non-hematological malignant tumors, malignant lymphomas (narrow), and skin malignant tumors (narrow) |  
| MACE                        | - For TULIP-1 and TULIP-2, MACE was those assessed by the CV-EAC  
- For MUSE, MACE was identified using a custom MedDRA term list  
- Was not included as a protocol-specified AESI in MUSE |  
| Non-SLE vasculitis          | - AEs with the PT hypersensitivity vasculitis or PT vasculitis  
- MUSE did not differentiate between SLE and non-SLE vasculitis |  

AE, adverse event; AESI, AE of special interest; CV-EAC, Cardiovascular Event Adjudication Committee; HLT, high-level term; MACE, major adverse cardiovascular event (CV death, nonfatal myocardial infarction, and nonfatal stroke); MedDRA, Medical Dictionary for Regulatory Activities; NIH, National Institutes of Health; PT, preferred term; SAE, serious adverse event; SMQ, standardized MedDRA Query; SOC, system organ class; TB, tuberculosis.

*a A patient with an event that met the criteria for more than one AE category was counted once in each category (eg, an AE that met the criteria for an AESI of herpes zoster and also met the criteria for an AESI of non-opportunistic serious infection was counted in both categories).  
*b For this integrated analysis, AESIs were identified from the datasets using standardized MedDRA queries (SMQ) and custom preferred term groupings as noted.  
*c Infusion-related reactions and hypersensitivity reactions were considered AESIs in MUSE, but not in this integrated analysis.
## Table S2. Baseline Demographics and Disease Characteristics in Pooled MUSE, TULIP-1, and TULIP-2 Data

|                          | Anifrolumab 300 mg (n=459) | Placebo (n=466) |
|--------------------------|-----------------------------|-----------------|
| Age, mean (SD), years    | 41.8 (12.0)                 | 40.7 (12.1)     |
| Female, n (%             | 426 (92.8)                  | 432 (92.7)      |
| Race, n (%)              |                             |                 |
| African American         | 65 (14.2)                   | 59 (12.7)       |
| American Indian/Alaskan Native | 8 (1.7)            | 2 (0.4)         |
| Asian                    | 44 (9.6)                    | 48 (10.3)       |
| White                    | 270 (58.8)                  | 284 (60.9)      |
| Other                    | 64 (13.9)                   | 65 (13.9)       |
| Missing                  | 8 (1.7)                     | 8 (1.7)         |
| Hispanic or Latino, n (%)| 132 (28.8)                  | 131 (28.1)      |
| Time from initial SLE diagnosis to randomization, median (range), months | 85.0 (0–555) | 75.3 (4–503) |
| IFNGS test-high status, n (%) | 373 (81.3) | 376 (80.7) |
| SLEDAI-2K score, mean (SD) | 11.2 (3.8)          | 11.4 (3.8)      |
| SLEDAI-2K score <10, n (%) | 145 (31.6)              | 141 (30.3)      |
| SLEDAI-2K score ≥10, n (%) | 314 (68.4)               | 325 (69.7)      |
| BILAG-2004 global score, mean (SD) | 19.3 (5.6) | 19.1 (5.3)   |
| At least 1 A, n (%)      | 226 (49.2)                  | 227 (48.7)      |
| No A and at least 2 Bs, n (%) | 211 (46.0)        | 209 (44.8)      |
| PGA score, median (range) | 1.8 (0.8, 2.8) | 1.8 (0.6, 2.8) |
| CLASI activity score, mean (SD) | 8.2 (7.3)           | 7.6 (6.8)       |
| SDI global score, mean (SD) | 0.6 (1.0)             | 0.6 (0.9)       |
| Abnormal complement concentration, n (%) |                     |                 |
| C3                       | 158 (34.4)                  | 179 (38.4)      |
| C4                       | 105 (22.9)                  | 109 (23.4)      |
| CH50                     | 48 (10.5)                   | 43 (9.2)        |
| Anti-dsDNA antibodies positive, n (%) | 191 (41.6) | 181 (38.8) |
| Cardiovascular risk at baseline, n (%) |                     |                 |
| Diabetes mellitus        | 26 (5.7)                    | 17 (3.6)        |
| Medical history of diabetes mellitus | 25 (5.4)  | 17 (3.6)       |
| Currently require therapy for diabetes mellitus | 22 (4.8)   | 15 (3.2)       |
| Hypertension             | 155 (33.8)                  | 134 (28.8)      |
| Medical history of hypertension | 154 (33.6)  | 133 (28.5)     |
| Currently require therapy for hypertension | 140 (30.5) | 116 (24.9)    |
| Hyperlipidemia           | 58 (12.6)                   | 74 (15.9)       |
| Medical history of hyperlipidemia | 58 (12.6) | 74 (15.9)     |
| Currently require therapy for hyperlipidemia | 34 (7.4)    | 80 (10.7)      |
| History of stroke        | 7 (1.5)                     | 12 (2.6)        |

Anti-dsDNA, anti–double-stranded DNA; BILAG-2004, British Isles Lupus Assessment Group-2004; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; IFNGS, Interferon gene signature; PGA, Physician’s Global Assessment; SD, standard deviation; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000.
### Table S3. Baseline SLE Medications in MUSE and in Pooled TULIP-1 and TULIP-2

|                     | Anifrolumab (300 mg; n=360) | Placebo (n=365) | Anifrolumab (300 mg; n=99) | Placebo (n=101) |
|---------------------|------------------------------|-----------------|---------------------------|-----------------|
| Glucocorticoids*   | 291 (80.8)                   | 303 (83.0)      | 79 (79.8)                 | 87 (86.1)       |
| Dosage, mean (SD)  | 9.5 (9.9)                    | 9.4 (8.2)       | 9.1 (7.3)                 | 11.14 (8.8)     |
| Dosage, median (range), mg/day | 10.0 (0–99.0)   | 10.0 (0–40.0)   | 10.0 (0–30.0)             | 10.0 (0–40.0)   |
| Dosage ≥10 mg/day, n (%) | 190 (52.8)               | 185 (50.7)      | 55 (55.6)                 | 64 (63.4)       |
| Antimalarials, n (%)^d | 243 (67.5)               | 266 (72.9)      | 76 (76.8)                 | 74 (73.3)       |
| Immunosuppressants, n (%) | 173 (48.1)            | 176 (48.2)      | 51 (51.5)                 | 45 (46.6)       |
| Azathioprine        | 62 (17.2)                   | 61 (16.7)       | 23 (23.2)                 | 19 (18.8)       |
| Methotrexate        | 56 (15.6)                   | 72 (19.7)       | 19 (19.2)                 | 16 (15.8)       |
| Mycophenolate       | 54 (15.0)                   | 45 (12.3)       | 11 (11.1)                 | 10 (9.9)        |
| Mizoribine          | 4 (1.1)                     | 3 (0.8)         | 0                         | 0               |

SD, standard deviation; SLE, systemic lupus erythematosus.

*Prednisone or equivalent.

^Includes patients not taking glucocorticoids at baseline. Their dosage is considered to be 0 mg/day at baseline.

^Includes glucocorticoids taken in combination with immunosuppressants and/or antimalarials.

^Includes antimalarials taken in combination with glucocorticoids and/or immunosuppressants.
Table S4. Number of Patients with Herpes Zoster Events During Treatment With Anifrolumab 1000 mg vs Placebo in MUSE and Anifrolumab 150 mg vs Placebo in TULIP-1

|                          | Anifrolumab 150 mg | Placebo | EAIR (per 100 PY) risk difference (anifrolumab 150 mg – placebo) (95% CI) | Anifrolumab 1000 mg | Placebo | EAIR (per 100 PY) risk difference (anifrolumab 1000 mg – placebo) (95% CI) |
|--------------------------|--------------------|---------|---------------------------------------------------------------------------|--------------------|---------|---------------------------------------------------------------------------|
|                          | (n=93)             | (n=184) |                                                                          | (n=105)            | (n=101) |                                                                          |
| Any AE                   | 5 (5.4)            | 3 (1.6) | 4.3 (–0.4, 11.9)                                                          | 9 (8.6)            | 1 (1.0) | 8.9 (2.4, 17.1)                                                           |
| Any AE with outcome of death | 0                  | 0       | 0                                                                         | 0                  | 0       | 0                                                                         |
| Any SAE                  | 0                  | 0       | 0                                                                         | 1 (1.0)            | 0       | 1.1 (–3.3, 5.9)                                                           |
| Any DAE                  | 1 (1.1)            | 0       | 1.2 (–1.1, 6.5)                                                           | 1 (1.0)            | 0       | 1.1 (–3.3, 5.9)                                                           |
| Any AE by maximum reported intensity |          |         |                                                                           |                    |         |                                                                           |
| Mild                     | 1 (1.1)            | 0       | ..                                                                        | 1 (1.0)            | 1 (1.0) | ..                                                                        |
| Moderate                 | 4 (4.3)            | 3 (1.6) | ..                                                                        | 6 (5.7)            | 0       | ..                                                                        |
| Severe                   | 0                  | 0       | ..                                                                        | 2 (1.9)            | 0       | ..                                                                        |

AE, adverse event; CI, confidence interval; DAE, adverse event leading to discontinuation of investigational product; EAIR, exposure-adjusted incidence rate; PY, patient-years; SAE, serious adverse event.

EAIR was reported per 100 PY and defined as the number of patients with the specific event divided by the total exposure time in years and then multiplied by 100. The exposure time was defined as the time from the date of first administration of investigational product to the date of first event, death, end of treatment plus 28 days, or end of study, whatever came first.
| Parameter, mean (SD) | Anifrolumab 300 mg (n=360) | Placebo (n=365) | Change from baseline |
|----------------------|-----------------------------|----------------|---------------------|
| Hemoglobin, g/L      | 125.0 (14.8) 125.3 (15.2) 0.5 (11) | 126.0 (15.2) 123.4 (15.9) −2.7 (11.3) |
| RBC                  | 4.3 (0.5) 4.4 (0.5) 0.1 (0.3) | 4.3 (0.5) 4.3 (0.5) −0.03 (0.3) |
| WBC                  | 5.5 (2.2) 6.6 (2.4) 1.1 (2.1) | 5.7 (2.4) 5.9 (2.7) 0.1 (2) |
| Lymphocytes          | 1.3 (0.6) 1.6 (0.7) 0.3 (0.6) | 1.3 (0.6) 1.3 (0.7) −0.03 (0.5) |
| Neutrophils          | 3.8 (1.8) 4.5 (2.0) 0.7 (1.8) | 4.0 (2.1) 4.1 (2.4) 0.1 (1.9) |
| Platelets            | 239.9 (78.2) 264.2 (81.2) 24.2 (58.2) | 250.2 (79.8) 252.7 (77.2) 3.2 (49.8) |
| GGT, U/L             | 30.9 (35.8) 25.6 (27.9) −4.6 (23.1) | 33.5 (73.9) 30.1 (39.4) −3.3 (26.1) |
| ALT, U/L             | 20.0 (12.8) 16.7 (9.8) −3.0 (11.5) | 21.5 (16.2) 20.6 (14.9) −0.8 (16.2) |
| AST, U/L             | 22.0 (12.0) 19.6 (7.8) −2.0 (8.2) | 22.3 (11.1) 23.2 (12.5) 0.8 (12.8) |
| Alkaline phosphatase, U/L | 68.6 (25.1) 73.0 (30.2) 4.6 (17.5) | 68.9 (28.9) 70.7 (27.4) 1.9 (17.8) |
| Albumin, g/L         | 41.8 (3.6) 41.7 (3.8) −0.1 (3.0) | 41.7 (3.8) 41.5 (4.1) −0.2 (3.1) |
| Bilirubin, μmol/L    | 6.5 (3.4) 6.6 (4.1) 0.1 (2.8) | 6.1 (3.0) 6.1 (2.9) 0.0 (2.4) |
| Calcium, mmol/L      | 2.3 (0.1) 2.3 (0.1) −0.002 (0.1) | 2.3 (0.1) 2.3 (0.1) −0.006 (0.1) |
| Sodium, mmol/L       | 138.4 (2.4) 138.8 (3) 0.4 (2.6) | 138.5 (2.5) 139.2 (2.5) 0.7 (2.7) |
| Potassium, mmol/L    | 3.9 (0.4) 4.0 (0.4) 0.1 (0.4) | 3.9 (0.4) 4.0 (0.4) 0.1 (0.4) |
| Glucose, mmol/L (fasted) | 4.9 (0.9) 4.9 (0.9) 0.03 (0.9) | 4.8 (0.8) 4.9 (1.0) 0.1 (1.0) |
| Urea nitrogen, mmol/L | 4.9 (2.0) 4.8 (1.8) −0.1 (1.5) | 4.9 (1.8) 4.9 (2.1) 0.1 (1.7) |
| Creatinine, μmol/L   | 66.8 (16.7) 67.1 (16.4) 0.1 (9.9) | 65.9 (17.1) 67.4 (20.0) 1.4 (11.8) |
| Creatine kinase, U/L | 72.6 (61.3) 88.866.5 17.9 (54.9) | 92.4 (160.8) 105.8 (177.0) 12.4 (154.8) |
| Cholesterol, mmol/L  | 4.9 (1.1) 4.9 (1.1) 0.1 (0.8) | 4.8 (1.1) 4.8 (1.1) 0.05 (0.7) |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; NA, not applicable; RBC, red blood cells; SD, standard deviation; WBC, white blood cells.
Table S6. Anti-drug Antibodies During Treatment in Pooled Data from TULIP-1 and TULIP-2

|                                | Anifrolumab 300 mg | Placebo   |
|--------------------------------|-------------------|-----------|
| ADA prevalence (positive at any visit, baseline, and/or post baseline), n/N/N (%) | 25/359 (7.0)     | 35/365 (9.6) |
| ADA persistently positive<sup>a</sup>, n/N/N (%) | 4/338 (1.2)       | 7/342 (2.0)  |
| nAb incidence<sup>b</sup>, n/N/N (%)        | 1/291 (0.3)       | 6/356 (1.7)  |

ADA, anti-drug antibodies; nAb, neutralizing antibodies.

<sup>a</sup>Treatment-induced ADA detected at 2 or more assessments (with ≥ 16 weeks between first and last positive) or detected at last assessment.

<sup>b</sup>nAb positive at post-baseline time points only (ie, nAb negative at baseline).
4. Supplementary Figures

Figure S1. Time to Discontinuation of Anifrolumab 300 mg vs Placebo in Pooled MUSE, TULIP-1, and TULIP-2 Data

Time since first dose in study (days)

Patients without discontinuation from investigational product (%)

Anifrolumab 300 mg
Placebo

n, number of patients still receiving investigational product at given time point.

For patients who completed investigational product, the time to discontinuation will be censored at the last dosing date plus 28 days.
5. References
1. Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by the BILAG index. *Rheumatology (Oxford)* 2003;42(11):1372–9.
2. Liu GF, Wang J, Liu K, et al. Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials. *Stat Med* 2006;25:1275–86.
3. Chuang-Stein C, Beltangady M. Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies. *Pharm Stat* 2011;10:3–7.
4. Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. *Clin J Am Soc Nephrol* 2010;5:2060–8.
5. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-second National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network symposium. *J Allergy Clin Immunol* 2006;117:391–7.
6. Shankar G, Atkin S, Cocea L, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. *AAPS J.* 2014;16:658–73.